CD8A and myeloid sarcoma: In this cohort, we do not see differences with regard to disease status in either the CD4+ or CD8+ subset, with the exception of a trend toward higher maximal VAF, and hence potentially higher clonality, for possibly damaging variants in CD4+ T cells of MS patients.